QLS-22001

N/A

Report date: 2023/11/10 13:58:30

Base Information

Drug NameQLS-22001
Drug Alias NameQLS22001QLS-22001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-17F blockersInterleukin 17A blockers
TargetsInterleukin-17FInterleukin 17A
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesQilu Pharmaceutical Co LtdShanghai Qilu Pharmaceutical R&D Center Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Qilu Pharmaceutical R&D Center Co LtdQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A